The Technical AnalystExchange: HKSE Sector: Pharmaceuticals Industry: Drug Manufacturers—Specialty & Generic
Fusen Pharmaceutical Price, Forecast, Insider, Ratings, Fundamentals & Signals
-1.12% HKD0.880
America/New_York / 3 mai 2024 @ 01:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 652.52 mill |
| EPS: | -0.0500 |
| P/E: | -17.60 |
| Earnings Date: | Mar 29, 2024 |
| SharesOutstanding: | 741.50 mill |
| Avg Daily Volume: | 0.125 mill |
| RATING 2024-05-02 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | n/a | n/a | n/a | |||
| Gr.Profit | n/a | n/a | n/a | |||
| Ebit | n/a | n/a | n/a | |||
| Asset | n/a | n/a | n/a | |||
| Debt | n/a |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -17.60 | sector: PE 23.82 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -1.34x |
| Company: PE -17.60 | industry: PE 13.09 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
HKD 0.828 - 0.932 ( +/- 5.91%) |
| ATR Model: 14 days |
Live Trading Signals (every 1 min)
10.00
Buy
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 |
| Volume Signals | |
|---|---|
| Price | HKD0.880 (-1.12% ) |
| Volume | 0.464 mill |
| Avg. Vol. | 0.125 mill |
| % of Avg. Vol | 372.38 % |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For 1652.HK
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
1652.HK
Fusen Pharmaceutical Company Limited, an investment holding company, manufactures and sells pharmaceutical products in the People's Republic of China. The company's product portfolio includes Shuanghuanglian-based cold medicines comprising Shuanghuanglian oral solutions and Shuanghuanglian injections; and flunarizine hydrochloride capsules and compound ferrous sulfate granules, as well as Yuanhu Zhitong oral solutions, Ganweikang tablets, and Yixinkang tablets. In addition, it researches, develops, produces, and sells various proprietary Chinese medicines and western medicine products for the treatment of cold and fever, cardiovascular diseases, and anemia. Further, the company offers business management and consulting services. Fusen Pharmaceutical Company Limited was founded in 2003 and is headquartered in Nanyang, China.